Mimmi Selena, Parrotta Elvira Immacolata, Tolomeo Anna Maria, Maisano Domenico, Crapella Valentina, Pingitore Elisabetta, Fatima Khushboo, Zimbo Anna Maria, Talarico Mariagrazia, Cristiani Costanza Maria, Scaramuzzino Luana, Valente Desirèe, Zannino Clara, Cuda Gianni, Quattrone Aldo, Iaccino Enrico, Quattrone Andrea
Neuroscience Research Center, Department of Medical and Surgical Sciences, University Magna Graecia of Catanzaro, Catanzaro, Italy.
Department of Medical and Surgical Sciences, University Magna Graecia of Catanzaro, Catanzaro, Italy.
Mov Disord. 2025 May 2;40(7):1420-6. doi: 10.1002/mds.30222.
Differentiating progressive supranuclear palsy (PSP) from other parkinsonian disorders may be challenging.
To investigate the role of transforming growth factor beta-1 (TGFβ1) in PSP.
A total of 33 PSP, 39 Parkinson's disease (PD), 8 multiple system atrophy (MSA) patients, and 50 healthy controls (HC) were enrolled. TGFβ1 levels, including both active and inactive forms (latency-associated peptide [LAP]-TGFβ1), were measured in serum, total extracellular vesicles (EVs), and neuronally-derived EVs (NDEVs) using microfluidic assays and ELISA.
PSP patients exhibited a marked increase in TGFβ1 and LAP-TGFβ1 levels in NDEVs, while no differences were observed across groups in serum or total EVs. Receiver operating characteristic (ROC) analysis demonstrated outstanding performance in differentiating PSP from non-PSP patients (TGFβ1, area under the curve [AUC]: 0.97; LAP-TGFβ1, AUC: 1.00), HC, AUC: 1.00).
This study highlights TGFβ1 and LAP-TGFβ1 in NDEVs as promising blood-based non-invasive biomarkers for PSP diagnosis, paving the way for further research on these proteins in PSP. © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
将进行性核上性麻痹（PSP）与其他帕金森病区分开来可能具有挑战性。
研究转化生长因子β1（TGFβ1）在PSP中的作用。
共纳入33例PSP患者、39例帕金森病（PD）患者、8例多系统萎缩（MSA）患者和50例健康对照（HC）。使用微流控分析和酶联免疫吸附测定法（ELISA）测量血清、总细胞外囊泡（EVs）和神经元来源的EVs（NDEVs）中的TGFβ1水平，包括活性和非活性形式（潜伏相关肽[LAP]-TGFβ1）。
PSP患者的NDEVs中TGFβ1和LAP-TGFβ1水平显著升高，而血清或总EVs在各组间未观察到差异。受试者工作特征（ROC）分析显示，在区分PSP与非PSP患者（TGFβ1，曲线下面积[AUC]：0.97；LAP-TGFβ1, AUC：1.00）、HC（AUC：1.00）方面表现出色。
本研究强调NDEVs中的TGFβ1和LAP-TGFβ1作为PSP诊断有前景的基于血液的非侵入性生物标志物，为进一步研究这些蛋白质在PSP中的作用铺平了道路。© 2025作者。《运动障碍》由Wiley Periodicals LLC代表国际帕金森和运动障碍协会出版。
